Journal Article

Susceptibility of clinical isolates of <i>Candida lusitaniae</i> to five systemic antifungal agents

Anne Favel, Annie Michel-Nguyen, Annick Datry, Svetlana Challier, Florence Leclerc, Christiane Chastin, Karim Fallague and Patrick Regli

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 53, issue 3, pages 526-529
Published in print March 2004 | ISSN: 0305-7453
Published online March 2004 | e-ISSN: 1460-2091 | DOI:
Susceptibility of clinical isolates of Candida lusitaniae to five  systemic antifungal agents

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care


Show Summary Details


Objectives: The aim of the present study was to expand the MIC database for Candidalusitaniae in order to further determine its antifungal susceptibility pattern.

Methods: The activities of amphotericin B, fluconazole, itraconazole, voriconazole and flucytosine were determined in vitro against 80 clinical isolates of C. lusitaniae. A set of 59 clinical isolates of Candida albicans and of 51 isolates of Candida glabrata was included to compare the susceptibilities to amphotericin B. The MICs were determined by Etest with RPMI 1640 agar, and with both this medium and antibiotic medium 3 (AM3) agar for testing of amphotericin B.

Results: All isolates were highly susceptible to fluconazole. The susceptibility to itraconazole was good; only 4% of isolates had dose-dependent susceptibility (MICs 0.25–0.5 mg/L). Voriconazole was very active in vitro (100% of isolates were inhibited at ≤0.094 mg/L). Flucytosine MICs ranged widely (0.004–>32 mg/L). The set included 19% of flucytosine-resistant isolates. For amphotericin B, 100% of isolates were inhibited at ≤0.75 mg/L (MIC50 0.047 mg/L; MIC90 0.19 mg/L) and at ≤4 mg/L (MIC50 0.25 mg/L; MIC90 0.75 mg/L) on RPMI and on AM3, respectively. A single isolate was categorized as resistant to amphotericin B (MIC 0.75 and 4 mg/L on RPMI and on AM3, respectively). Amphotericin B thus appeared very active in vitro against C. lusitaniae. Whatever the test medium, the level of susceptibility of C. lusitaniae to amphotericin B did not differ much from those of C. albicans and C. glabrata.

Conclusion: C. lusitaniae appears to be susceptible to amphotericin B, azole antifungal agents, and, to a lesser extent, flucytosine.

Keywords: Keywords: C. lusitaniae, antifungals, susceptibility patterns, Etest

Journal Article.  1882 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.